Saturday, September 26, 2026

Abridged - Capital Cycle IQ & Forensic Files on the Big 5 Hyperscalers (MSFT, AMZN, ORCL, META, GOOG)

Microsoft, Amazon, Oracle, Meta and Alphabet face another two years of record AI data-center investment amid $3 trillion in commitments, leases, guarantees and potential off-balance-sheet…

ORCL $419B

Cassandra Unchained Sep 26 9 clicks

Sep 26 HONA $49B

New Buy : Honeywell Aerospace $HONA

D Invests 13 clicks

Sep 26 VBNK $720M

VersaBank: The Bank Behind the Bank – How a Canadian Branchless Pioneer Wants to Make Asset-Backed Securities Obsolete

Substack von Philipp 5 clicks

From X

@valuedontlie Sep 26

Colin King on X

To $FOUR credit, they've already been buying back lots of stock and recently killed the Up-C structure (which are terrible) https://t.co/0kRHGBybWV https://t.co/BBTKz873dC

@Fierce__beast Sep 26

Fierce_beast on X

@brianjrobben I mention this possibility as a reason for why it sold down too. I don't think 8% returns are bad for $MCD, but yea, it's not obviously good here. At the same time i'm a bit torn given i am short many resturants this idea maybe is a bit of an idea to balance my book a bit.

@AltayCapital Sep 26 2 clicks

AltayCap on X

The only industries where obvious capital allocation lingo is useful is leasing / banking / insurance. It's much more nebulous in operating businesses that do real things. $AER ceo saying the cheapest commercial jets are on the NYSE under the ticker AER is easy to understand. As math is pencilling out cost of new orders vs buying back stock. $FOUR competes in the real world. Leasing/banking products are fungible. Much harder biz to forecast. Cap allocation is still important, but a lot harder.

@Fierce__beast Sep 26 1 click

Fierce_beast on X

@theotheraharon But i'm looking for ideas that have been specifically impacted by the degrossing event. Not sure $MXCT or $RARE are correlated to that. The idea is find stocks that are irrationally selling off or getting bid due to the degrossing, then pick your spots from the list you find.

@Fierce__beast Sep 26

Fierce_beast on X

@SolutionOrganic There are other reasons, beyond the return to buy it. But my base case is closer to 8% here. But there are reasons for instance that if inflation rise or rates increase, i think bonds would suffer more than $MCD and $otis at this valuation if you look out 1 year

@Fierce__beast Sep 26

Fierce_beast on X

I guess the issue with buying corporate debt is what if interest rates keep going up or if there is inflation? Fixed rate coupon at 6% you might need to wait till maturity to get paid back. But what if there's also increased inflation? according to blackrock it looks like weighted average maturity is like 9-10 years or so for their BBB index $LQDP. With $MCD and $OTIS i think you get a 6%+ total return in most inflation or interest rate environments at these valuations, hopefully more. I was underwriting something closer to 7-8% for both those stocks personally, but probably 6% would be OK, as I am 200% leveraged long and maybe gonna go higher, so expected return on my equity from these ideas is closer to 12%, maybe 16%. But then adds some other benefits that seem decently valuable, like MCD beta .4, otis .88, defensively better than a lot of stocks in case of a recession. Maybe $MCD is just getting degrossed as everyone leveraged it up on their portfolios at the same time expecting an accepetable return of lets say 5% but leveraged 2x or more they were getting a 10%+ ROE on thier protfolio and now degrossing it at the same time. Not totally sure if i'm underwriting correctly, or if this is the best idea in the world, seemed just OK.

@Fierce__beast Sep 26 1 click

Fierce_beast on X

@JJNews002 bought a little of it too $ABVX

@Fierce__beast Sep 26 1 click

Fierce_beast on X

What are people buying and selling in this apparent biotech degrossing phase? I am looking given the irrationality of the situation and the temporary opportunities it may present on both sides of the ledger. $XBI recent returns seem driven by two stocks $MRNA and $TWST. I shorted small size some $CDNA, $MRVI. Long $ACAD, $UTHR and $CELC. Are these completely idiotic ideas?

GitLab: Positioned To Benefit From Software Development Explosion

GitLab's Q2 FY2027 beat and raised guidance reflect large deals, paid consumption growth and AI demand, while valuation rests on revenue…

GTLB $8.2B

Research and Value Sep 26 3 clicks

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

FGPR $254MPRTH $642M

Nat Stewart - Stock Picking Newsletter Sep 25 12 clicks

The Enron-Era Tricks Are Back in AI: How These Companies Are Hiding Their Debt | The Weekly Wrap

Steve Eisman says AI companies are reviving Enron-era off-balance-sheet and circular financing, alongside concerns around Oracle and Blue…

ORCL $419B

Steve Eisman Sep 25 5 clicks

Reddit: DCF Valuation

Reddit’s DCF values shares at $225, driven by international ARPU expansion from $2.2 to $8.3 by 2035 and 38% operating margins.

RDDT $28B

Hated Moats Sep 25 7 clicks

Oklo: Shares Have Plunged, But I'm Still Bearish

Oklo shares have fallen 77% since October 2025 as commercialization slips beyond 2027, revenue estimates fall and dilution continues.

OKLO $6.7B

Ian Bezek Sep 25 5 clicks

TSOH Weekly Roundup (09/25/2026)

TSOH Weekly Roundup covers Ralph Lauren’s $1 billion distribution pullback, Peloton’s $2,195 foldable treadmill and $800 million…

RL $21BPTON $2.2B

TSOH Investment Research Sep 25 5 clicks

IonQ: Nvidia QPU Catalyst Isn't Enough

IonQ's Q2 2026 revenue rose 287% to $80.1 million, but durability hinges on its $485 million RPO and enterprise adoption for production AI…

IONQ $18B

Deep Value Investing Sep 25 2 clicks

Single Stock Spotlight #15: Rocket Companies (RKT)

Rocket Companies combines Redfin, Rocket Mortgage and Mr. Cooper into an end-to-end homeownership platform, adding mortgage servicing fees…

RKT $33B

Hidden Rock Capital's Newsletter Sep 25 6 clicks

Eckert & Ziegler: The Pick-and-Shovel Supplier of the Radiopharma Boom – Finally at a Fair Price

Eckert & Ziegler trades near €12, about 14 times expected earnings, as its isotope supply business expands with radiopharma demand despite…

NVS $271B

Substack von Philipp Sep 25 3 clicks

(Public) Mach Natural Resources - A Buying Opportunity

Mach Natural Resources' Q2 distributable cash fell to $60.1 million as development spending rose, prompting a distribution cut; its units…

MNR $1.7B

HFI Research Sep 25 4 clicks

TMCR · short

Metals Royalty Company INC

Metals Royalty Company, a U.S.-focused critical-minerals royalty platform, direct-listed on Nasdaq in April 2026 and holds royalty and…

TMCR $211M

Value Investors Club May 25

Shift4 Payments: A Fintech Compounder Trading Like a Melting Ice Cube

Shift4 Payments earns 50 to 60 basis points on SkyTab volume while acquiring merchant networks, driving 39% annual GRLNF growth since 2021…

FOUR $2.9B

Modern Value Investing Mar 15

Pershing Square U.S. and Pershing Square Inc. Dual Listings

Pershing Square plans dual IPOs of PSUS and management company PSI, granting 20 PSI shares for every 100 PSUS shares to counter closed-end…

PS $22B

Eagle Point Capital Mar 14

Lands’ End Into Next Week: A Re-Rate Catalyst Hiding Behind Tender Noise

Lands’ End’s March 19 results could clarify the WHP IP joint venture, debt paydown and retained stake, supporting a rerating beyond the…

LE $309M

Rod’s Ruminations Mar 13

Single Stock Spotlight #4: Global Payments (GPN)

Global Payments trades below 6 times adjusted earnings and about 7 times free cash flow amid Worldpay, competition and debt concerns.

GPN $22B

Hidden Rock Capital's Newsletter Mar 13

MAPS: Fortifying the Record Before the Bid

MAPS reported $39.8 million of FY25 adjusted EBITDA and $62.4 million of cash as a holder builds a record around a possible affiliated bid.

MAPS $56M

Rod’s Ruminations Mar 13

✅ Buying AI Beneficiaries and Selling One AI-disrupted Business

Sleep Well Portfolio is selling SPS Commerce as AI-vulnerable and adding Veeva, Mercado Libre, Cellebrite and Sea, citing proprietary data,…

VEEV $45BCLBT $2.8B

Sleep Well Investments Mar 12

FactSet’s Take-Private Rumours

FactSet has drawn take-private interest from Thoma Bravo and Hellman & Friedman, with its recurring subscription revenue, 90% client…

FDS $9.6B

Global Outperformers Mar 11

Visa Inc update

Visa and Mastercard meet a 15% five-year IRR target at 25x and 26x 2026 earnings, while American Express needs more margin for…

MA $494BAXP $204B

Global Outperformers Mar 11

We Dramatically Improved our Machine Learning Model to Price Kalshi Earnings Contracts. It Went 11/13.

A two-layer machine-learning model correctly called 11 of 13 CrowdStrike earnings-word contracts on Kalshi, using historical transcripts…

CRWD $279B

First Strike Research Mar 7

Saturday, September 26, 2026

Colin King on X

Fierce_beast on X

AltayCap on X

Fierce_beast on X

Fierce_beast on X

Fierce_beast on X

Fierce_beast on X

Fierce_beast on X

Investor Letters

Publications we follow

Newsletters 93

YouTube 4

Blogs 12

Seeking Alpha 43 of 207

X accounts we follow

Investor letters we follow

Sectors